CytoAgents

Cyto Agents

Biotechnology, 100 S Commons, Pittsburgh, Pennsylvania, 15212, United States, 1-10 Employees

cytoagents.com

  • facebook
  • LinkedIn

Who is CYTOAGENTS

CytoAgents is a clinical stage biotechnology company focused on the development of innovative pharmaceutical products for the treatment of life-threatening symptoms associated with Cytoki...

Read More

map
  • 100 S Commons, Pittsburgh, Pennsylvania, 15212, United States Headquarters: 100 S Commons, Pittsburgh, Pennsylvania, 15212, United States
  • 2018 Date Founded: 2018
  • 1-10 Employees: 1-10
  • dollar-icon Revenue: $1 Million to $5 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 8731 | NAICS Code: 541715 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from CYTOAGENTS

CytoAgents Org Chart and Mapping

Employees

Jodi Craigo

Chief Science Officer

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding CytoAgents

Answer: CytoAgents's headquarters are located at 100 S Commons, Pittsburgh, Pennsylvania, 15212, United States

Answer: CytoAgents's official website is https://cytoagents.com

Answer: CytoAgents's revenue is $1 Million to $5 Million

Answer: CytoAgents's SIC: 8731

Answer: CytoAgents's NAICS: 541715

Answer: CytoAgents has 1-10 employees

Answer: CytoAgents is in Biotechnology

Answer: CytoAgents contact info: Phone number: Website: https://cytoagents.com

Answer: CytoAgents is a clinical stage biotechnology company focused on the development of innovative pharmaceutical products for the treatment of life-threatening symptoms associated with Cytokine Release Syndrome (CRS), an overreaction of the immune system causing systemic inflammation. There are many causes of CRS and our mission is to develop a broadly accessible treatment for multiple indications of high unmet need. Using a novel approach by calming the natural immune response to a multi organ disease, CytoAgemts' lead drug candidate, GP1681, is positioned to become a new best practice in medicine.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access